

CHARLES D. BAKER Governor KARYN E. POLITO

Lieutenant Governor

The Commonwealth of Massachusetts

Executive Office of Health and Human Services
Department of Public Health
Bureau of Health Professions Licensure
239 Causeway Street, Suite 500, Boston, MA 02114

Tel: 617-973-0800 TTY: 617-973-0988 www.mass.gov/dph/boards MARYLOU SUDDERS Secretary MONICA BHAREL, MD, MPH Commissioner

1

S	TERII	Æ	COMPO	OUNDING	REPORTING	7 FORM

January 1 - June 30 _____(year)
July 1 - December 31 _____(year)

All Massachusetts pharmacies that are licensed by the Massachusetts Board of Registration in Pharmacy ("Board") and engage in compounding of sterile products are required to complete and submit product, volume, distribution, and compliance data every six months pursuant to 247 CMR 6.15(5). This reporting process is designed to ensure that all pharmacies licensed by the Board that perform sterile compounding are in compliance with all state and federal laws and regulations, including in particular the United States Pharmacopeia (USP) General Chapter 797 Pharmaceutical Compounding – Sterile Preparations. The completed form must be submitted to the Board on or before August 15 for the first half of the year or February 15 for the second half.

Massachusetts pharmacies that do **not** engage in **sterile compounding, as defined in** USP General Chapter 797, are **NOT** required to submit this form to the Board. Hospital pharmacies engaged in sterile compounding are not required to submit this form at this time.

The FAILURE of any Massachusetts pharmacy that performs sterile compounding to provide the requested information to the Board by the deadline may be grounds for discipline under 247 CMR 10.03(q).

Any Massachusetts pharmacy that performs sterile compounding that does NOT provide the requested information to the Board by the required date is NOT authorized to engage in sterile compounding and must IMMEDIATELY CEASE preparing and dispensing all sterile products.

Please **electronically** submit the Sterile Compounding Reporting Form and Table of CSP Prescriptions found at: http://www.mass.gov/eohhs/gov/departments/dph/programs/hcq/dhpl/pharmacy/mandated-reporting-forms-.html to sterilecompoundingreportingforms@massmail.state.ma.us **Please Note:** Table of CSP Prescriptions must be submitted using Board provided template in **Excel format only** (i.e. not pdf versions).

All questions regarding the Sterile Compounding Reporting Form and /or the Table of CSP Prescriptions should be directed to William Frisch, Director of Pharmacy Compliance at William.Frisch@state.ma.us or Michelle Chan, Quality Assurance Pharmacist at Michelle.Chan@State.MA.US.

7D1 1	
Thank	VOII
1 Hank	vou.

Name of Pharmacy:		
Name of Pharmacu		
rame of Finalmacy.		

January 1 - June 30 _____(year)
July 1 - December 31 _____(year)

Name of Massachusetts Pharmacy				
Street Address				
City/Town				
Tel. No Fax No.	·			
Pharmacy E-mail				
MA Drug Store Permit Numbers:				
Drug Store (DS No.)	Exp. Date			
Controlled Substance (CS No.)	Exp. Date			
List any other registrations below related to the Massachusetts Pharmacy (e.g., manufacturer, wholesale distributor):				
DEA Registration No.	_			
DCP Registration No.	_			
FDA Registration No.	_ (manufacturer/distributor only)			
Other:	_			

STERILE COMPOUNDING REPORTING FORM January 1 - June 30 (year)

July 1 – December 31 _____(year)

Answer all of the following questions for the specified reporting period ONLY

A. STERILE COMPOUNDING ACTIVITY:

1. Indicate the total number of prescriptions dispensed by month and by USP General Chapter 797 risk-level category (low, medium, high) for the reporting period listed below:

Low Risk Compounding: single volume transfers of not more than 3 sterile dosage forms and not more than 2 entries into a sterile container (e.g., hydrating solutions, irrigations, antibiotics and oncology medications).

Medium Risk Compounding: the compounding process includes complex aseptic manipulations other than single volume transfer (e.g., TPN, cardioplegia solutions, multiple sterile ingredient admixtures).

High Risk Compounding: non-sterile ingredients, including manufactured products not intended for sterile routes of administration, are incorporated or a non-sterile device is employed before terminal sterilization.

Total Number of Prescriptions / Orders				
		Risk Level		
Month/Volume	# Low	# Medium	# High	Total

2. Does the pha	armacy hold a license in any other state than Massachusetts?
∐Yes	□No
•	all other state(s) in which the pharmacy holds a license and indicate the status of each cense as: active, expired, on probation, restricted or revoked.
Alabama	☐ Active ☐ Expired ☐ Probation ☐ Restricted ☐ Revoked
Alaska	Active Expired Probation Restricted Revoked
Arizona	Active Expired Probation Restricted Revoked
☐ Arkansas	☐Active ☐Expired ☐Probation ☐Restricted ☐Revoked
☐ California	☐Active ☐Expired ☐Probation ☐Restricted ☐Revoked
☐ Colorado	☐Active ☐Expired ☐Probation ☐Restricted ☐Revoked
☐ Connecticut	d
Delaware	☐Active ☐Expired ☐Probation ☐Restricted ☐Revoked
☐ D.C.	☐Active ☐Expired ☐Probation ☐Restricted ☐Revoked
☐ Florida	☐Active ☐Expired ☐Probation ☐Restricted ☐Revoked
☐ Georgia	☐Active ☐Expired ☐Probation ☐Restricted ☐Revoked
Name of Pl	narmacy:

January 1 - June 30	(year)	
July 1 – December 31	(year)	

Hawaii	Active	□ Expired	☐ Probation	Restricted	Revoked
Idaho	Active	□ Expired	☐ Probation	Restricted	Revoked
Illinois	Active	□ Expired	☐ Probation	Restricted	Revoked
Indiana	Active	□ Expired	□ Probation	Restricted	Revoked
bwa	Active	□ Expired	□ Probation	Restricted	Revoked
Kansas	Active	□Expired	□Probation	☐ Restricted	Revoked
Kentucky	Active	□ Expired	□ Probation	Restricted	Revoked
Louisiana	Active	□ Expired	□ Probation	Restricted	Revoked
Maine	Active	□ Expired	☐ Probation	Restricted	Revoked
Maryland	Active	□ Expired	☐ Probation	Restricted	Revoked
Michigan	Active	□ Expired	☐ Probation	Restricted	Revoked
Minnesota	Active	□ Expired	☐ Probation	Restricted	Revoked
Mississippi	Active	□ Expired	☐ Probation		Revoked
Missouri	Active	□ Expired	☐ Probation	Restricted	Revoked
Montana	Active	□ Expired	☐ Probation	Restricted	Revoked
Nebraska	Active	□ Expired	☐ Probation	Restricted	Revoked
Nevada	Active	□ Expired	☐ Probation	Restricted	Revoked
New Hampshire	Active	□ Expired	☐ Probation	Restricted	Revoked
New Jersey	Active	□ Expired	☐ Probation		Revoked
New Mexico	Active	□ Expired	☐ Probation	_	Revoked
New York	Active	☐ Expired			Revoked
North Carolina	Active	□ Expired	_		Revoked
North Dakota	Active	□ Expired	☐ Probation		Revoked
Ohio	Active	Expired	☐ Probation		Revoked
Oklahoma	☐Active	□ Expired	☐ Probation		Revoked
Oregon	☐Active	☐ Expired	☐ Probation		Revoked
Pennsylvania	☐Active	☐ Expired	☐ Probation		Revoked
Rhode Island	Active	□ Expired			Revoked
South Carolina	Active	Expired	Probation		Revoked
South Dakota	Active	Expired	Probation		Revoked
Tennessee	Active	□ Expired	☐ Probation	_	Revoked
Texas	Active				_
Utah	Active	Expired		Restricted	
Vermont	Active	Expired	Probation		
Virginia	Active	Expired			
Washington	Active	Expired	Probation	Restricted	Revoked
West Virginia	Active	Expired	Probation	Restricted	Revoked
Wisconsin	Active			Restricted	Revoked
Wyoming	Active		Probation	Restricted	Revoked
Other	Active	Expired	Probation	Restricted	Revoked
Other	Active	☐ Expired	☐ Probation	Restricted	Revoked

(vear)

January 1 - June 30

July 1 – December 31 (year) 3. Does the pharmacy dispense Compounded Sterile Preparations (CSPs) to any states and/or jurisdictions outside of Massachusetts? □Yes \square No If yes, identify all state(s) and jurisdictions outside of Massachusetts which the pharmacy dispenses to. □ Alabama ☐ Illinois □ Nebraska ☐ South Carolina □ Alaska □ Indiana □ Nevada ☐ South Dakota ☐ Arizona ☐ Iowa ☐ New Hampshire ☐ Tennessee □ Kansas □ New Jersey ☐ Texas ☐ Arkansas ☐ New Mexico □ Utah □ California ☐ Kentucky ☐ Colorado ☐ Louisiana □ New York □ Vermont ☐ Connecticut □ Maine ☐ North Carolina ☐ Virginia ☐ Delaware ☐ Maryland ☐ North Dakota ☐ Washington \square D.C. ☐ Michigan □ Ohio ☐ West Virginia ☐ Oklahoma ☐ Florida ☐ Minnesota ☐ Wisconsin ☐ Mississippi ☐ Georgia ☐ Oregon ☐ Wyoming ☐ Hawaii ☐ Missouri ☐ Pennsylvania Other: ☐ Idaho □ Montana ☐ Rhode Island Other: 4. Is the pharmacy currently registered, licensed, or permitted as a wholesale distributor in any state? □Yes \square No If yes, identify all other state(s) which the pharmacy is currently registered, licensed, or permitted as a wholesale distributor. ☐ Alabama ☐ Illinois □ Nebraska ☐ South Carolina □ Alaska □ Indiana □ Nevada ☐ South Dakota ☐ Arizona ☐ Iowa ☐ New Hampshire ☐ Tennessee ☐ Kansas ☐ New Jersey ☐ Arkansas ☐ Texas ☐ California ☐ Kentucky ☐ New Mexico □ Utah □ Colorado ☐ Louisiana □ New York □ Vermont ☐ Connecticut ☐ North Carolina ☐ Virginia ☐ Maine □ Delaware ☐ Maryland ☐ North Dakota ☐ Washington \square D.C. ☐ Michigan □ Ohio ☐ West Virginia ☐ Florida ☐ Minnesota ☐ Oklahoma ☐ Wisconsin ☐ Georgia ☐ Wyoming ☐ Mississippi ☐ Oregon ☐ Hawaii ☐ Missouri ☐ Pennsylvania Other: _____ ☐ Idaho □ Montana ☐ Rhode Island ☐Other: _____

STERILE COMPOUNDING REPORTING FORM January 1 - June 30 (year)

(year)

July 1 – December 31 _____

5. Identify all wholesale distributors, including both contracted entities and manufacturers, that the pharmacy receives products from, including chemicals, medications, syringes, vials, and other related equipment and materials required to produce CSPs: Amerisource Bergen ☐ Fagron ☐ McKesson ☐ American Reagent ☐ FFF Enterprises ☐ Medical Specialties \square Anda ☐ Gallipot ☐ Medisca ☐ Apothecare Products ☐ Haemonetics ☐ Medline $\prod APP$ ☐ HD Smith \square MSD \square ASD ☐ Healthcare Logistics \square ODC ☐ Healthcare Technologies \prod PCCA ☐ Attentus ☐ Baxter ☐ Hospira ☐ Sagent ☐ Bbraun ☐ Independence Medical ☐ Sandor Pharm ☐ Integrated Medical ☐ Smiths Medical ☐ Bellco \prod IMS ☐ Sun Pharmaceuticals ☐ Bio Soln ☐ CAPS- Birmingham \square JOM ☐ Vygon ☐ CAPS- Chicago ☐ Kinray ☐ West Ward ☐ CAPS- Lehigh Valley ☐ Letco ☐ Wolf Medica ☐ Letzo ☐ Other: _____ ☐ Cardinal ☐ Other: _____ CSL Behring ☐ Liberty Industries ☐ Cubist ☐ Lifeline 6. Identify all manufacturers that provide the pharmacy with non-sterile Active Pharmaceutical Ingredients (API): \square Anda ☐ Letco □ PCCA ☐ Other: _____ ☐ Bellco ☐ Mallinckrodt Group ☐ Other: _____ ☐ Fagron □ McKesson ☐ Freedom ☐ Medisca \square ODC ☐ Gallipot

	G/COMPETENCY EVALUATION	ONS:
1.a) Identify by name, title and l	icense number of all pharmacy pers	sonnel engaged in preparing CSPs.
(Attach additional pages if a	• /	License#_
Name		
Name	Title	License#
b) State the current number of CSPs	pharmacists involved in any way in	the preparation and/or dispensing of
State the current number of dispensing of CSPs.	pharmacy technicians involved in a —	any way in the preparation and/or
2. Do all pharmacists and phar have documented training c		reparation and/or dispensing of CSPs
□Yes □No		
	macy technicians involved in the property scheduled competency validation	reparation and/or dispensing of CSPs n every 12 months?
□Yes □No		
If yes, specify the frequency of	competency validations:	
☐ Every month	☐ Every 5 months	☐ Every 9 months
Every 2 months	Every 6 months	Every 10 months
☐ Every 3 months ☐ Every 4 months	☐ Every 7 months ☐ Every 8 months	☐ Every 11 months ☐ Every 12 months

January 1 - June 30	(year)
July 1 – December 31	(year)

C. QUALITY ASSURANCE

Please complete the following table			
Type of Equipment/Resources	How many of each does the pharmacy have?	Have they been ISO certified within the past 6 months?	
Laminar air flow hoods			
Biological safety cabinets (BSCs)			
Compounding Aseptic Isolators (CAIs, glove boxes)			
Compounding Aseptic Containment Isolators (CACIs)			
Clean rooms, positive pressure			-
Ante Rooms, positive pressure			
Clean rooms, negative pressure			
1. a) Identify all sterilization proces Filter	ses used by pharmacy: Dry Heat	Other:	_
b) Does the pharmacy follow US: Yes No N/A	P <797> standards for steri	lization of CSPs?	
c) If used, does the pharmacy pro- sterile components in the prepa		vials, non-sterile stoppers,	, or any other nor
□Yes □No □N/A			

Name of Pharmacy: _____

STERILE COMPOUNDING REPORTING FORM January 1 - June 30 ______(year)

3. When was the most recent USP <797> Gap Analysis completed? ___/___ (mm/dd/yyyy)4. Does the Pharmacy have a data driven Quality Assurance/Performance Improvement Program?

☐Yes ☐No5. Does the pharmacy always use USP <797> Beyond-Use-Dating?

If the pharmacy does not always use USP <797> Beyond-Use-Dating, answer the following questions:

a) For what risk level(s) does the pharmacy extend the USP <797> Beyond-Use-Date?

☐ Low ☐ Medium ☐ High

b) What is the pharmacy's longest Beyond-Use-Date (in days)? ____ and what is this CSP's risk level?

☐ Low ☐ Medium ☐ High

c) Does the pharmacy use scientific literature in order to establish Beyond-Use-Dating?

[Yes No

d) Does the pharmacy independently validate its Beyond-Use-Dating?

□Yes □No

 \square Yes

 \square No

January 1 - June 30	(year)
July 1 – December 31	(year)

D . (\mathbf{COMPL}	JAN	CE/S	SAN	CTIO	NS

1.	Does the pharmacy only prepare and dispense CSPs after receipt of a valid prescription for a single patient?						
	□Yes	□No					
2.	Check all ri	isk levels of CSPs the	pharmacy prepared of	luring the reporti	ng period.		
	□ Low		☐ Medium		High		
3.	Does the pharmacy maintain a written policy and procedure manual for preparing and dispensing Compounded Sterile Preparations in conformance with USP <797>?						
	□Yes	□No					
4.	Did the pha	rmacy engage in batc	ch compounding of C	SPs during this re	eporting period?		
	□Yes	□No					
If y	ves:						
a)	How many	y units were in the lar	gest batch? (Units= 1	cassette, 1 bag,	1 syringe, etc.)		
b)	Does the p	pharmacy perform ste	rility testing on all ba	tches?			
	□Yes	□No					
	If no, ple	ase explain why not.					
c)	Does the p	harmacy perform end	lotoxin testing on all	batches?			
	□Yes □No						
	If no, ple	ase explain why not.					
5.	Has the pha	ırmacy been disciplin	ed, as defined in 247	CMR 6.15, durir	ng the reporting period?		
	□Yes	□No					
If y	ves:						
a)	Did the pharmacy report the disciplinary action(s) to the Massachusetts Board of Registration in Pharmacy?						
	□Yes	□No					
	If no, ple	ease explain why not.					
Ide	ntify the age	ency or agencies that	disciplined the pharm	acy:			
_	N/A		☐ FDA		Arkansas BORP		
_	Medicare		☐ Alabama BORP		California BORP		
=	Medicaid DEA		☐ Alaska BORP ☐ Arizona BORP		☐ Colorado BORP ☐ Connecticut BORP		
_							

STERILE COMPOUNDING REPORTING FORM January 1 - June 30 (vear)

	J	anuary 1 - June 30	(year)			
	J	uly 1 – December 31	(year)			
	Delaware BORP D.C. BORP Florida BORP Georgia BORP Hawaii BORP Idaho BORP Illinois BORP Indiana BORP Indiana BORP Kansas BORP Kentucky BORP Louisiana BORP Maine BORP Maryland BORP		Pennsylvania BORP Rhode Island BORP South Carolina BOR South Dakota BORP Tennessee BORP Texas BORP Utah BORP Vermont BORP Virginia BORP Washington BORP West Virginia BORP Wisconsin BORP Wyoming BORP			
片	Maryland BORP Michigan BORP	☐ Oklahoma BORP ☐ Oregon BORP	Other: ☐Other:			
6.						
If :	yes:					
a)	 a) Did the pharmacy report this change in status to the Massachusetts Board of Registration in Pharmacy? \[\sum_{Yes} \text{No} \] 					
b)	b) For which accreditation organization(s)?					
	PCAB	☐ Joint Commission	☐ Other	_		

STERILE COMPOUNDING REPORTING FORM January 1 - June 30 (year) July 1 - December 31 (year)

Ε.	T DOTEST		REPORTI		
н.		AIIVH. I	RRPURII	NI - KH	 VIRINIS

1.	Fill out the Table of CSP Prescriptions for This Reporting Period in Excel that is provided on the Board's website under Mandated Reporting Forms.				
2.	What is the number of in-state individual sterile compounded prescriptions or orders for end users your pharmacy has dispensed during this reporting period?				
3.	What is the number of out-of-state individual sterile compounded prescriptions or orders for end users your pharmacy has dispensed during this reporting period?				
4.	Have the MOR and all pharm	acists and technicians on staff completed all required CE credits?			
	□Yes □No				
5.	List the name and title of the pharmacy; not just sterile con	MOR and all principal managers (include all current managers in the apounding).			
	Name	Title			
	Name	Title			
	Name	Title			
	Name	Title			
	Name	Title			
	Name	Title			
	Name	Title			
	Name	Title			
6.	6. Attach a list of the name and title of every employee at the facility (remember to include all non-licensed and non-pharmacy individuals).				
7.	. Is the pharmacy compliant with all requests for information by the Massachusetts Board of Registration in Pharmacy?				
	□Yes □No				

STERILE COMPOUNDING REPORTING FORM January 1 - June 30 (year) July 1 - December 31 (vear)

	July 1 – Decem	ber 31	_(year)
Attestation regardi	ng compliance with laws a	nd regulations:	
pharmacy), attest un pharmacy) is in com USP General Chapte dispenses medicatio	der the pains and penalties of apliance with all laws and reger 797 - Sterile Preparations. In pursuant to a valid prescrip	of perjury that gulations pertinent to ption as defined in M	(name of (name of (name of (name of pharmacy) only I.G.L. c. 94C, §19 for a single chusetts or out-of-state patient.
Print Name of Mana	ger of Record:	MA I	License Number:
Signature of Manag	er of Record:		Date:
· -	state.ma.us or Michelle Char		, Director of Pharmacy Compliance Pharmacist at
DO NOT submit the accepted. Thank yo	•	E-mail. Mailed pape	er and faxed copies will not be